Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Operating Income: 2013-2024

Historic Operating Income for Summit Therapeutics (SMMT) over the last 11 years, with Dec 2024 value amounting to -$226.0 million.

  • Summit Therapeutics' Operating Income fell 81.20% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$180.7 million, marking a year-over-year decrease of 92.35%. This contributed to the annual value of -$226.0 million for FY2024, which is 62.93% up from last year.
  • Latest data reveals that Summit Therapeutics reported Operating Income of -$226.0 million as of FY2024, which was up 62.93% from -$609.6 million recorded in FY2023.
  • Summit Therapeutics' Operating Income's 5-year high stood at -$53.2 million during FY2020, with a 5-year trough of -$609.6 million in FY2023.
  • For the 3-year period, Summit Therapeutics' Operating Income averaged around -$302.6 million, with its median value being -$226.0 million (2024).
  • Its Operating Income has fluctuated over the past 5 years, first plummeted by 745.69% in 2023, then surged by 62.93% in 2024.
  • Summit Therapeutics' Operating Income (Yearly) stood at -$53.2 million in 2020, then slumped by 62.03% to -$86.2 million in 2021, then climbed by 16.36% to -$72.1 million in 2022, then crashed by 745.69% to -$609.6 million in 2023, then skyrocketed by 62.93% to -$226.0 million in 2024.